From Sample to Signal: How Biospecimen Quality Impacts Multiomic Assay Development
Multiomic research allows scientists to examine biology across multiple layers, combining information from genomics, transcriptomics, epigenetics, proteomics, and other molecular measurements.
By integrating these different data types, researchers can develop a more complete picture of cellular function, disease progression, treatment response, and biological variation. Modern multiomic platforms increasingly support combinations of single-cell analysis, spatial transcriptomics, protein measurement, methylation analysis, and sequencing-based workflows.
However, the quality of the resulting data depends on more than the analytical platform.
Every result begins with a biological sample.
Donor selection, sample type, collection procedures, processing timelines, storage conditions, and freeze-thaw history can all affect the molecular and cellular signals measured during an experiment. When these variables are poorly controlled, even highly sensitive analytical technologies may produce results that are difficult to reproduce or interpret.
For researchers developing and validating multiomic assays, biospecimen quality must therefore be considered part of the experimental design.
Multiomic Assays Place Greater Demands on Starting Material
Traditional experiments may measure a single class of biological information, such as DNA variants or the concentration of a specific protein.
Multiomic workflows can simultaneously or sequentially examine several analyte classes from the same donor or sample. These may include:
- Genomic DNA
- Cell-free DNA
- Messenger RNA and other RNA species
- Protein expression
- DNA methylation
- Chromatin accessibility
- Immune-cell composition
- Cellular phenotype and function
Each analyte responds differently to collection, handling, processing, and storage conditions.
RNA, for example, may be especially sensitive to degradation and processing delays. Protein measurements may be affected by temperature, clotting, proteolysis, or repeated freeze-thaw cycles. Single-cell applications depend heavily on cell viability, cell-type recovery, and the preservation of representative cellular populations.
Because these effects can be analyte-specific, a sample that performs adequately in one assay may not be suitable for another.
Pre-analytical procedures should therefore be standardized and evaluated in relation to the intended downstream application. Research has shown that the effects of pre-analytical variability can differ across genes, transcripts, proteins, biomarkers, and analytical methods.
Selecting the Appropriate Biospecimen Type
The first major decision is choosing the sample type that best aligns with the scientific objective.
PBMCs
Peripheral blood mononuclear cells include lymphocytes and monocytes and are commonly used for:
- Immune profiling
- Single-cell sequencing
- Transcriptomic analysis
- Immunophenotyping
- Functional cell assays
- Biomarker discovery
- Assay development and validation
PBMC quality may be influenced by the anticoagulant used, transportation time, processing method, cryopreservation protocol, thawing procedure, and the time between collection and isolation.
For single-cell workflows, viability alone may not provide a complete picture of sample quality. Researchers must also consider whether specific cell populations were disproportionately lost or altered during processing.
A sample may show acceptable overall viability while still having a cell-type distribution that differs from the original blood specimen.
Whole Blood
Whole blood may be appropriate when researchers need:
- Direct DNA or RNA extraction
- Broad blood-based biomarker assessment
- Assay-development material
- Hematology-related measurements
- Matched cellular and plasma fractions
- Validation of extraction or processing workflows
Whole blood can reduce some of the processing steps required before analysis, but it introduces other variables, including anticoagulant choice, storage time, temperature, and cell stabilization.
The intended analyte should guide how whole blood is collected and transported.
Plasma
Plasma is frequently used in:
- Cell-free DNA research
- Circulating tumor DNA studies
- Liquid-biopsy assay development
- Proteomic analysis
- Extracellular RNA studies
- Circulating biomarker discovery
- Molecular residual disease research
The concentration of a target molecule in plasma may be extremely low. This makes sample handling particularly important.
Delayed plasma separation can increase contamination from lysed blood cells. Centrifugation procedures, collection-tube selection, storage temperature, and freeze-thaw cycles can also affect downstream results.
Reviews of liquid-biopsy workflows have identified study population, biofluid selection, sample collection, handling, processing, and storage as important sources of pre-analytical variation.
Leukopaks
Leukopaks provide a concentrated source of peripheral blood immune cells and may be preferred when research requires:
- High cellular yield
- Multiple immune-cell isolations
- Large assay-development runs
- Repeated validation experiments
- Manufacturing process development
- Cell selection and enrichment
- Matched cellular fractions
Because one leukopak can provide a large number of cells from a single donor, it can reduce the need to combine material from multiple donors during early development work.
This may help researchers distinguish true assay variability from differences caused by donor pooling or inconsistent starting material.
Isolated Immune-Cell Populations
Purified cell populations, such as T cells, B cells, monocytes, natural killer cells, or CD34-positive cells, can support targeted assay development.
Isolated cells may be useful when researchers need to:
- Validate cell-type-specific markers
- Develop targeted sequencing panels
- Evaluate assay sensitivity
- Establish positive and negative controls
- Reduce background from unrelated cell populations
- Compare performance across known cell types
Isolation method, purity, viability, activation state, and recovery should be documented because each can influence downstream molecular measurements.
Pre-Analytical Variables That Can Change the Signal
Multiomic assays are designed to detect biological differences. The challenge is ensuring those differences originate from the biology rather than from inconsistent sample handling.
Several pre-analytical variables deserve close attention.
Donor Selection
Donor characteristics may introduce meaningful biological variation, including:
- Age
- Sex
- Disease status
- Medication use
- Smoking history
- Body mass index
- Recent illness
- Collection time
- Treatment history
- Previous donations
These variables are not necessarily problems. In many studies, they are central to the research question.
The problem occurs when donor characteristics are undocumented, inconsistently applied, or unevenly distributed across study groups.
Well-defined inclusion and exclusion criteria can help researchers control expected variation and interpret unexpected results.
Collection Tubes and Anticoagulants
Collection-tube selection can affect cell behavior, nucleic-acid stability, clotting, and plasma quality.
EDTA, heparin, citrate, cell-stabilization tubes, and serum tubes are not interchangeable. The appropriate option depends on the sample type, analyte, processing timeline, and downstream assay.
Collection materials should be selected during assay development rather than treated as a logistical decision after the protocol has been finalized.
Time to Processing
The interval between collection and processing can influence:
- Cell viability
- RNA integrity
- Gene-expression profiles
- Protein stability
- Cell activation
- Cell-type recovery
- Hemolysis
- Release of genomic DNA into plasma
Processing delays can produce changes that resemble biological responses.
For example, cellular stress during extended storage may alter transcriptional profiles. In plasma workflows, delayed separation may increase background DNA released from leukocytes.
Researchers should define an acceptable processing window and apply it consistently across all samples.
Temperature and Transportation
Temperature fluctuations during shipment can affect cells, proteins, nucleic acids, and other biological components.
Transportation plans should address:
- Ambient, refrigerated, or frozen conditions
- Temperature monitoring
- Packaging validation
- Maximum transportation time
- Weekend and holiday delays
- Shipment-to-processing handoff
- Procedures for temperature excursions
For prospective collections, coordination between the collection site, courier, processing laboratory, and research team can be as important as the collection itself.
Cryopreservation and Thawing
Cryopreservation allows samples to be collected over time and analyzed in controlled batches. This can reduce day-to-day analytical variation.
However, freezing and thawing may affect:
- Cell viability
- Cell recovery
- Cell-type composition
- Surface-marker expression
- RNA quality
- Cellular activation
- Functional performance
Consistency is critical.
Researchers should define and document freezing medium, cooling rate, storage temperature, thawing procedure, wash steps, resting periods, and post-thaw acceptance criteria.
The goal is not simply to achieve a high viability percentage. It is to preserve material that remains fit for the intended assay.
Freeze-Thaw History
Repeated freeze-thaw cycles can degrade sensitive analytes and increase variability.
Whenever possible, plasma, serum, and other liquid samples should be divided into appropriately sized aliquots before long-term storage.
This allows researchers to thaw only the volume required for each experiment while preserving untouched aliquots for later validation.
Matching Samples Across Multiple Analytes
One of the most valuable approaches in multiomic research is collecting several material types from the same donor.
A matched collection may include:
- Whole blood
- PBMCs
- Plasma
- Serum
- Isolated immune cells
- Genomic DNA
- RNA
- Bone marrow, when appropriate
Matched samples allow researchers to compare molecular signals across analytes while reducing variability caused by using unrelated donors.
For example, plasma-based biomarkers can be evaluated alongside immune-cell composition or gene-expression data from the same participant.
This can be especially useful in:
- Biomarker discovery
- Oncology research
- Autoimmune-disease studies
- Longitudinal monitoring
- Translational assay development
- Patient-stratification research
- Multiomic reference dataset generation
Recallable Donors and Longitudinal Research
A recallable-donor program provides the ability to collect additional material from the same donor at a later time.
This may support:
- Repeat assay-development runs
- Lot bridging
- Longitudinal studies
- Reproducibility testing
- Expanded sample-volume needs
- Protocol comparison
- Additional analyte collection
- Follow-up disease or treatment data
Recallability can be particularly valuable when a donor has a rare phenotype, specific diagnosis, required biomarker profile, or well-characterized clinical history.
It also allows teams to investigate whether an unexpected result can be reproduced in a new collection from the same individual.
Standardization Without Eliminating Biological Diversity
Multiomic research often requires diverse, representative donor populations. Standardization should not mean removing meaningful biological variation.
Instead, it should mean controlling the operational variables that could obscure that biology.
Researchers can support this objective by consistently documenting:
- Donor eligibility criteria
- Collection materials
- Draw volume
- Time of collection
- Time to processing
- Transportation conditions
- Processing method
- Storage duration
- Number of freeze-thaw cycles
- Cell counts and viability
- Isolation purity
- Available donor metadata
This information helps analytical teams determine whether an observed signal is biological, procedural, or technical.
Designing Biospecimen Collections Around the Assay
The best time to consider biospecimen strategy is before assay development begins.
A fit-for-purpose collection plan should address:
- The analytes being measured
- The required sample type
- Minimum volume or cellular yield
- Donor inclusion and exclusion criteria
- Required clinical or demographic data
- Collection-tube and anticoagulant requirements
- Processing and stability windows
- Fresh versus cryopreserved material
- Testing and characterization requirements
- Shipping and delivery conditions
- Need for matched or longitudinal samples
- Expected scale during validation and commercialization
Early planning can prevent researchers from developing an assay around material that will be difficult to source consistently at a larger scale.
It can also reduce the need to change sample formats, processing procedures, or acceptance criteria late in development.
Supporting the Full Path From Sample to Signal
Multiomic platforms are becoming increasingly capable of integrating genomic, transcriptomic, proteomic, epigenetic, single-cell, and spatial data. Illumina, for example, currently positions its multiomic tools around the integration of these data types and has expanded into connected analysis, single-cell research, spatial transcriptomics, and whole-genome oncology workflows.
As analytical sensitivity and complexity increase, the quality of the starting sample becomes more important, not less.
A sophisticated platform can identify subtle molecular signals, but it may also detect subtle inconsistencies introduced during collection, shipping, processing, or storage.
Reliable multiomic assay development therefore requires coordination across the entire workflow, from donor recruitment and specimen collection to analytical processing and data interpretation.
CGT Global supports research teams with fresh and cryopreserved PBMCs, leukopaks, whole blood, plasma, serum, isolated cell populations, custom donor criteria, and prospective collection programs.
Collection and processing strategies can be designed around project-specific requirements, including matched materials, repeat donors, disease-state cohorts, custom testing, specialized processing, and delivery schedules.
By treating biospecimen quality as part of the assay rather than simply an input, researchers can improve reproducibility, reduce avoidable variability, and generate data that more accurately reflects the underlying biology.
Planning a Multiomic or Assay-Development Project?
CGT Global can help your team evaluate sample type, donor criteria, collection procedures, processing requirements, testing, and delivery logistics for your research workflow.
